jens juul holst glp-1 Researcher receives prize for huge contribution to modern treatment of diabetes and obesity Dr. Jens Juul Holst on

GLP-1 analogues are often prescribed for chronic conditions such as type 2 diabetes and obesity, which require ongoing, long-term management

Stopping tirzepatide will not immediately stop the current shedding cycle because the trigger occurred months ago

These criteria were established to isolate the impact of GLP-1 prescriptions on study outcomes while controlling for potential confounding factors, with a specific focus on the risk of depression, anxiety, and suicide

Consistency outweighs intensity: Long-term sustainable habits produce results that short-term interventions cannot

[18] Access considerations are important for patients to understand: Referral to Tier 3 or 4 specialist weight management services is required for NHS-funded weight management treatment with GLP-1 agonists Local formularies may restrict which GLP-1 agonists are available Supply shortages have affected availability, particularly for higher-dose formulations Private prescriptions may be necessary for those not meeting NHS criteria Ongoing monitoring and specialist input are typically required Patients interested in GLP-1 agonist therapy should discuss their individual circumstances with their GP, who can advise on local referral pathways to specialist services if appropriate

If you begin treatment with lower muscle mass, you face greater vulnerability to functional losses